Investing Ideas
/
Indian Pharmaceuticals & Biotech Undervalued based on future growth

Indian Pharmaceuticals & Biotech Undervalued based on future growth

Name: Financial Insights Based on S&P Global Market Intelligence
Creator: Simply Wall St Pty Ltd
License: https://www.spglobal.com/content/dam/spglobal/corporate/en/documents/secure/MI-FastTrack-Terms-and-Conditions-July-2023.pdf

Results

1 new

Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)

1 companies

Strides Pharma Science

Market Cap: ₹75.7b

Develops and manufactures pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally.

New

STAR

₹821.80

-13.9%

-22.9%